Equity

Total Equity

United Therapeutics Total Equity decreased by 16.8% to $5.90B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 13.3%, from $6.81B to $5.90B. Over 5 years (FY 2020 to FY 2025), Total Equity shows an upward trend with a 15.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementBalance Sheet Statement
SectionEquity
CategoryCapital Allocation
SignalHigher is better
VolatilityStable
First reportedQ4 2013
Last reportedQ1 2026

How to read this metric

An increase generally signals growth in retained earnings or capital injections, while a decrease may indicate share buybacks, dividend payments, or net losses.

Detailed definition

This represents the residual interest in the assets of the entity after deducting all its liabilities. It reflects the n...

Peer comparison

Standard across all public companies; peers in the medical device and diagnostics sector typically maintain high equity levels to support R&D and M&A.

Metric ID: total_stockholders_equity

Historical Data

20 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$3.64B$3.83B$3.96B$4.18B$4.32B$4.56B$4.80B$5.12B$5.41B$5.71B$5.98B$5.34B$5.70B$6.10B$6.44B$6.81B$7.17B$6.59B$7.10B$5.90B
QoQ Change+5.2%+3.4%+5.5%+3.4%+5.6%+5.1%+6.8%+5.6%+5.6%+4.8%-10.8%+6.7%+7.1%+5.6%+5.6%+5.4%-8.1%+7.7%-16.8%
YoY Change+18.7%+19.1%+21.2%+22.7%+25.3%+25.2%+24.8%+4.2%+5.3%+6.8%+7.7%+27.5%+25.9%+8.0%+10.1%-13.3%
Range$3.64B$7.17B
CAGR+10.7%
Avg YoY Growth+14.9%
Median YoY Growth+18.9%

Frequently Asked Questions

What is United Therapeutics's total equity?
United Therapeutics (UTHR) reported total equity of $5.90B in Q1 2026.
How has United Therapeutics's total equity changed year-over-year?
United Therapeutics's total equity decreased by 13.3% year-over-year, from $6.81B to $5.90B.
What is the long-term trend for United Therapeutics's total equity?
Over 5 years (2020 to 2025), United Therapeutics's total equity has grown at a 15.9% compound annual growth rate (CAGR), from $3.40B to $7.10B.
What does total equity mean?
The total value of the company that belongs to the shareholders after all debts are paid.